Page last updated: 2024-11-12

gamendazole

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

gamendazole: Spermatogenesis Blocking Agents; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

gamendazole : A member of the class of indazoles that is 3-(indazol-3-yl}prop-2-enoic acid carrying additional 2,4-dichlorobenzyl and trifluoromethyl substituents at positions 1 and 6 respectively. An orally active antispermatogenic compound with antifertility effects that is a potential male contraceptive drug. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID11212172
CHEMBL ID514569
CHEBI ID90703
SCHEMBL ID1050488
MeSH IDM0524207

Synonyms (26)

Synonym
(2e)-3-[1-(2,4-dichlorobenzyl)-6-(trifluoromethyl)-1h-indazol-3-yl]prop-2-enoic acid
gamendazole
CHEMBL514569
chebi:90703 ,
SCHEMBL1050488
DTXSID4042676
877773-32-5
trans-3-(1-benzyl-6-(trifluoromethyl)-1h-indazol-3-yl)acrylic acid
(2e)-3-{1-[(2,4-dichlorophenyl)methyl]-6-(trifluoromethyl)-1h-indazol-3-yl}prop-2-enoic acid
Q5520039
877766-45-5
(e)-3-[1-[(2,4-dichlorophenyl)methyl]-6-(trifluoromethyl)indazol-3-yl]prop-2-enoic acid
kyyqmvukyqcsqy-aatrikpksa-n
2-propenoic acid, 3-[1-[(2,4-dichlorophenyl)methyl]-6-(trifluoromethyl)-1h-indazol-3-yl]-, (2e)-
(2e)-3-[1-[(2,4-dichlorophenyl)methyl]-6-(trifluoromethyl)-1h-indazol-3-yl]-2-propenoic acid
trans-3-[1-(2,4-dichlorobenzyl)-6-trifluoromethyl-1h-indazol-3-yl]-2-propenoic acid
2-propenoic acid, 3-[1-[(2,4-dichlorophenyl)methyl]-6-(trifluoromethyl)-1h-indazol-3-yl]-
3-(1-((2,4-dichlorophenyl)methyl)-6-(trifluoromethyl)-1h-indazol-3-yl)-2-propenoic acid
3-(1-(2,4-dichlorobenzyl)-6-(trifluoromethyl)-1h-indazol-3-yl)acrylic acid
2-propenoic acid, 3-(1-((2,4-dichlorophenyl)methyl)-6-(trifluoromethyl)-1h-indazol-3-yl)-, (2e)-
trans-3-(1-(2,4-dichlorobenzyl)-6-trifluoromethyl-1h-indazol-3-yl)-2-propenoic acid
unii-x75z3rsn5m
(2e)-3-(1-((2,4-dichlorophenyl)methyl)-6-(trifluoromethyl)-1h-indazol-3-yl)-2-propenoic acid
x75z3rsn5m ,
(e)-3-(1-(2,4-dichlorobenzyl)-6-(trifluoromethyl)-1h-indazol-3-yl)acrylic acid
AKOS040745807

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Similarly, oral dosing of WIN 18,446, which inhibits testicular retinoic acid biosynthesis, effectively contracepts rabbits."( New approaches to male non-hormonal contraception.
Amory, JK; Nya-Ngatchou, JJ, 2013
)
0.39
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
Hsp90 inhibitorAn EC 3.6.4.10 (non-chaperonin molecular chaperone ATPase) inhibitor that blocks the action of heat shock protein 90.
eukaryotic translation elongation factor 1alpha 1 inhibitorAny compound that inihibits the human protein, eukaryotic translation elongation factor 1alpha 1.
synthetic oral contraceptiveAn oral contraceptive which owes its effectiveness to synthetic preparation.
antispermatogenic agentAn agent that destroy spermatozoa in the male genitalia and block spermatogenesis.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (5)

ClassDescription
indazoles
alpha,beta-unsaturated monocarboxylic acidA monocarboxylic acid in which the carbon of the carboxy group is directly attached to a C=C or C#C bond.
olefinic compoundAny organic molecular entity that contains at least one C=C bond.
dichlorobenzeneAny member of the class of chlorobenzenes carrying two chloro groups at unspecified positions.
organofluorine compoundAn organofluorine compound is a compound containing at least one carbon-fluorine bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID1469107Binding affinity to recombinant human eEF1A1 expressed in HEK293 cells by ITC2018Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7
Identification of Eukaryotic Translation Elongation Factor 1-α 1 Gamendazole-Binding Site for Binding of 3-Hydroxy-4(1 H)-quinolinones as Novel Ligands with Anticancer Activity.
AID392675Neuroprotection against beta-amyloid peptide 1-42-induced toxicity in retinoic acid-differentiated human SH-SY5Y cells assessed as lactate dehydrogenase release2009Bioorganic & medicinal chemistry, Feb-15, Volume: 17, Issue:4
Neuroprotective activity and evaluation of Hsp90 inhibitors in an immortalized neuronal cell line.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (30.00)29.6817
2010's4 (40.00)24.3611
2020's3 (30.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 21.70

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index21.70 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index4.80 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (21.70)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (20.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (80.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]